Clinical evaluation of ipratropium bromide combined withβreceptor agonistsin treatment of asthma in children
- VernacularTitle:异丙托溴铵联合β2受体激动剂治疗儿童哮喘的临床疗效评价
- Author:
Tao LIN
- Publication Type:Journal Article
- Keywords:
ipratropium bromide;
βreceptor agonists;
salbutamol;
asthma;
children
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):130-132
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effects and safety of ipratropium bromide combined with β receptor agonists in treatment of asthma in children. Methods The patients were divided into control group and therapy group randomly. On the basis of the treatment for asthma, the control group and therapy group were treated with ipratropium bromide, ipratropium bromide combined with salbutamol, respectively. Results After treatment, the clinical symptoms such as cough, suffocated feeling, cyanosis and dififcult breathing were improved on different degree for both of the two groups. The levels of lung function indexes including FVC、FEV 1、FEV 1% and PEF and the total effective rate in therapy group were signiifcantly higher than the control group. Besides, no signiifcant adverse effect was observed. Conclusion The ipratropium bromide combined with salbutamol can be used to relieve asthma in children effectively and synergistically. The bioavailability and the compliance of children are good.
